{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:08Z","timestamp":1791571748086,"version":"4.3.4"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives and Methods<\/jats:title><jats:p>We conducted a multicenter retrospective study to analyze the safety and efficacy of DPd versus DKd in daratumumab na\u00efve RRMM patients treated in real\u2010world practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 187 patients with RRMM were included in the analysis; 128 patients received DPd, and 59 patients received DKd. A vast majority (80%) of patients had lenalidomide refractory disease and nearly 50% had bortezomib refractory disease. The overall response and complete response rates were 76% and 34% in the DPd group versus 80% and 51% in the DKd group, respectively. With a median follow up of 36\u2009months for the entire patient population, median PFS and OS in the DPd versus DKd groups were 12, 12, 37, and 35\u2009months, respectively. The most common grade 3+ adverse events in the DPd versus DKd groups were neutropenia (32% vs. 7%), anemia (14% vs. 10%), thrombocytopenia (13% vs. 15%), and cardiovascular events (4% vs. 15%), respectively. Both DPd and DKd appeared to be a safe and effective treatment options for RRMM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While there were more cytopenias associated with DPd and more cardiovascular side effects with DKd, there were no significant differences in the survival outcomes with these two regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14193","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:08:58Z","timestamp":1708560538000},"page":"975-983","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab\u2010na\u00efve relapsed multiple myeloma"],"prefix":"10.1111","volume":"112","author":[{"given":"Danai","family":"Dima","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology Cleveland Clinic, Taussig Cancer Institute  Cleveland Ohio USA"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mansour","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematology\/Oncology Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Minchak","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Medical University of South Carolina School of Medicine  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Cleveland Clinic, Taussig Cancer Institute  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Atallah","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Logan","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"University of Kansas School of Medicine  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Tabak","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"University of Kansas School of Medicine  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Rashid","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u2010Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC)  Westwood Kansas USA"},{"name":"Division of Hematology\/Oncology Medical University of South Carolina  Charleston South Carolina USA"},{"name":"Division of Hematology\/Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S212526"},{"issue":"3","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the international myeloma working group","volume":"22","author":"Moreau P","year":"2021","journal-title":"Lancet Oncol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072160"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703233"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123527"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"issue":"8","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","journal-title":"Lancet Oncol"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"issue":"10","key":"e_1_2_10_17_1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open\u2010label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos MA","year":"2023","journal-title":"Lancet Haematol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0813-1"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:36:43Z","timestamp":1714113403000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ejh.14193"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14193","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"2024-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}